• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home StudyGraphics

#VisualAbstract: Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer

byAlisha Yi
October 4, 2023
in StudyGraphics
Reading Time: 2 mins read
#VisualAbstract: Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
Share on FacebookShare on TwitterShare on LinkedIn

1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%).

2. More patients in the I-SABR group experienced grade 3 immunological adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Standard treatment for early-stage inoperable non-small-cell lung cancer (NSCLC) includes stereotactic ablative radiotherapy (SABR). However, relapses remain common. Although immunotherapy may has shown efficacy in stage III NSCLC, its efficacy in earlier stages remains unknown. This randomized controlled trial aimed to compare the outcomes of SABR alone with SABR combined with immunotherapy (I-SABR) in early-stage NSCLC patients. The primary outcome was four-year event-free survival, while key secondary outcome was the assessment of adverse events associated with treatment. According to study results, I-SABR significantly improved event-free survival at four years in people with early-stage NSCLC, compared to SABR alone. Although this study was well done, it was limited by its phase 2 nature, and further confirmation with larger phase 3 trials is warranted.

Click to read the study in The Lancet

Relevant Reading: Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

RELATED REPORTS

Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer

Continuation of immunotherapy after immune checkpoint inhibitor-induced myocarditis in patients with lung cancer may be safe and effective

FDA approvedFor non-small cell lung cancer: Jideytro (zidesamtinib), Jul 22, 2026→

In-depth [randomized-controlled trial]: Between Jun 30, 2017, and Mar 22, 2022, 183 patients were assessed for eligibility across three hospitals in Texas, USA. Included were patients ≥ 18 years with early-stage NSCLC (IA-IB, IIA-IIB) who were medically inoperable or had isolated parenchymal recurrences. Altogether, 156 patients (78 each in SABR and I-SABR) were included in the final analysis. The primary outcome of 4-year event-free survival was significantly greater in the I-SABR group (77%) compared to SABR alone (53%; hazard ratio 0.38, 95% CI 0.19-0.75; p=0.0056). Moreover, the secondary outcome showed that I-SABR offered improved event-free survival in early-stage NSCLC with tolerable toxicity. More patients in the I-SABR group experienced grade 3 immunological adverse events related to nivolumab (15% in I-SABR vs. 0% in SABR). Overall, findings from this study suggest that I-SABR could be used as a treatment option for early-stage NSCLC.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: immunotherapylung cancerNivolumabnon-small cell lung cancer (NSCLC)oncologypulmonology
Previous Post

Pilot program of chronic hepatitis B treatment in Ethiopia

Next Post

Nurse-delivered sleep restriction therapy effective for treatment of chronic insomnia

RelatedReports

Immunotherapy collage: an immune T cell meeting a cancer cell, Y-shaped antibodies and a small key on teal paper
Gastroenterology

Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer

November 20, 2026
Lung cancer immunotherapy collage: engraved lungs and trachea, a cluster of round immune cells and a folded surgical towel
Cardiology

Continuation of immunotherapy after immune checkpoint inhibitor-induced myocarditis in patients with lung cancer may be safe and effective

November 19, 2026
A liver illustration with spilled sugar cubes and two drink cups, highlighting the link between sugary drinks and liver health.
Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Next Post

Nurse-delivered sleep restriction therapy effective for treatment of chronic insomnia

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets

Association between changes in carbohydrate intake and long term weight changes

#VisualAbstract: Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia

#VisualAbstract: Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.